India : The Board of Directors of MedPlus Health Services Limited, in its meeting on February 2, 2024, has just approved the unaudited standalone and consolidated financial results of the Company for the quarter ending December 31, 2023.
Unaudited Consolidated Financial Results for the Quarter and Nine month period ended December 31, 2023
| All Numbers are in Rs Millions | Quarter Ended 31.12.2023 | Quarter Ended 30.09.2023 | Quarter Ended 31.12.2022 |
|---|---|---|---|
| Total Income | 14,512.63 | 14,189.54 | 12,016.75 |
| Total Expenses | 14,313.01 | 14,025.10 | 11,854.62 |
| Profit/ (loss) before tax | 199.62 | 164.44 | 162.13 |
| Net Profit after tax | 137.05 | 145.44 | 133.81 |
| Total comprehensive income for the period | 149.57 | 168.21 | 131.80 |
| EPS(Basic) | 1.15 | 1.22 | 1.20 |
MedPlus Health Services Limited Financial Results Highlights :
Revenue :
- There was a ₹ 2,512 million increase compared to Q3FY23, representing a 21.1% year-over-year (YoY) growth.
- Additionally, there was a ₹ 329 million increase compared to Q2FY24, reflecting a 2.3% quarter-over-quarter (QoQ) increase.
- Furthermore, there was a 0.7% increase in private label sales compared to Q3FY23.
Store Additions :
- 144 Store Net Additions
- There were 164 gross additions.
- 89 net additions beyond Tier-One.
- The total number of stores stood at 4,233 as of December 31, 2023.
Pharmacy Operating EBITDA :
- The Pharmacy division achieved a 3.6% Operating EBITDA margin, which increased by 40 basis points (bps) quarter-over-quarter (QoQ).
- The Company’s Operating EBITDA amounted to ₹ 466 million.